10-Q · May 13, 2026
Sensus Healthcare reported a disappointing Q1 2026 with revenues of $3.4 million, a significant decline of 59.0% from $8.3 million year-over-year. The company also posted an EPS loss of -$0.16, missing estimates, driven…
Earnings analysis · 10-Q
SRTS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Sensus reported a weak second quarter, with revenue of $2.29 million down 68.5% year over year and diluted EPS of $(0.53), materially below the $(0.09) consensus estimate. Gross margin improved sequentially to 34.8%…
Read full summary
Sensus reported a weak second quarter, with revenue of $2.29 million down 68.5% year over year and diluted EPS of $(0.53), materially below the $(0.09) consensus estimate. Gross margin improved sequentially to 34.8% from 29.2% but remained below the 39.7% prior-year level. Management cited eight units shifted to Q3, a proposed 26% reimbursement increase, and 153% website-user growth as offsets, but provided no formal quantitative guidance and the filing does not include updated risk-factor disclosure.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.53
- Gross margin
- 34.8%
What stood out
-
Revenue declined 68.5% year over year
Second-quarter revenue was $2.29 million, down 68.5% year over year and below the $4.60 million consensus estimate. Management attributed part of the shortfall to eight units shifting into the third quarter.
-
EPS loss widened materially
Diluted EPS was $(0.53), versus $(0.06) in Q2 2025 and the $(0.09) consensus estimate, indicating substantially greater losses than both the prior-year quarter and expectations.
-
Gross margin improved sequentially
Gross margin was 34.8%, an improvement from 29.2% in Q1 2026 but below 39.7% in Q2 2025, representing a 5.6-percentage-point sequential increase and a 4.9-point year-over-year decline.
-
Proposed reimbursement increase
Management highlighted a proposed 26% reimbursement increase as a potential commercial tailwind, although the filing does not quantify its expected revenue impact.
-
Website traffic rose 153%
Website users increased 153%, which management cited as an improving commercial indicator despite the quarter's revenue and unit-volume decline.
-
Secured financing arrangements added
The filing includes a June 2, 2026 loan agreement, revolving promissory note, pledged collateral and restricted account agreement, and security agreement with City National Bank of Florida, indicating new or expanded secured financing arrangements during the quarter.
What to watch
-
Severe revenue and volume contraction
Revenue was $2.29 million, down 68.5% year over year, while management also cited lower unit volume. The shift of eight units to Q3 highlights continued sensitivity to order timing and quarterly delivery concentration.
-
Losses materially exceeded expectations
Diluted EPS was $(0.53), compared with $(0.06) in the year-ago quarter and $(0.09) consensus, signaling substantially greater losses and a significant earnings miss.
-
Year-over-year margin compression
Gross margin of 34.8% remained 4.9 percentage points below the 39.7% reported in Q2 2025, despite improving 5.6 points sequentially from Q1 2026. Sustained margin pressure could limit the company's ability to fund operations internally.
-
No updated risk-factor disclosure
The company states under Item 1A that, as a smaller reporting company, it is not required to provide risk-factor disclosure in this Form 10-Q. Consequently, material changes versus the prior 10-K or 10-Q cannot be fully assessed from this filing.
Management's outlook
Management said it remains focused on delivering strong performance in the second half of 2026, but provided no formal quantitative revenue or EPS guidance.
Earlier filings 4
10-Q · August 12, 2025
Sensus Healthcare reported Q2 revenue of $7,315,000 (down from $9,239,000 a year ago) and GAAP diluted EPS of $(0.06). Gross margin compressed to 39.7% and operating margin swung to a loss of (26.6%) as operating…
10-K · March 5, 2025
Sensus Healthcare positions itself as a niche medical-device company focused on superficial radiation therapy (SRT) with an installed base of 867 units in 21 countries and FDA-cleared SRT-100 product family. The 10-K…
10-Q · November 13, 2023
Sensus reported Q3 revenue of $3,898,000 and GAAP diluted EPS of $(0.09), a sharp decline from $9,010,000 revenue and $0.11 EPS in Q3 2022. Gross profit fell to $1,989,000 (51.0% margin) and the company recorded an…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.